Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib in Metastatic Triple-negative Breast Cancer
NCT01575522Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2012
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivantinib in triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 6 months. Started Mar 2012; status: completed.
02
Drugs
tivantinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01575522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01575522.